Addressing Anemia and Quality of Life Through Current Evidence and Guideline-Based Practice in Lower-Risk Myelodysplastic Syndrome

Podcast 2: Treatment and Follow Up
Post-Test/Evaluation

Questions marked with a * are required

19%

Contact Information

First Name

Last Name

Email Address

Credentials/Degree (MD, DO, RN, etc.)

Date of Participation

What is one of the major problems that may occur with repeated transfusions, and often leads to a need for more targeted therapy for MDS?

Iron overload

Protein overload

Platelet overload

B-cell overload

A 67-year-old woman has a bone marrow biopsy with the following results: hypercellular for age

(57%), with morphology revealing 4% blasts; 3% ring sideroblasts; and immunohistochemistry

showing CD34+. Erythroid hyperplasia, and dysmegakaryopoiesis are also observed. Cytogenetics

shows del(5q) MDS subtype. Next-generation sequencing shows DNMT3A mutations (no IDH2 or

TP53 mutations). If the patient fails supportive care with transfusions, which of the following

targeted agents might be most effective, particularly given her high percentage of ring

sideroblasts?

Luspatercept

Lenalidomide

Azacitidine

Decitabine